IRF2 and hepatocellular carcinoma: Other studies have shown that Sp1, IRF1 and IRF2 can bind to the APOL1 promoter in hepatoma cells [40], and IRF1, IRF2 and STAT2 to the APOL1 promoter in podocytes and endothelial cells [17].